Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/45832
Title: Hyperadrenocorticism in Dogs
Authors: Behrend, Ellen N.
Melián Limiñana, Carlos 
UNESCO Clasification: 310907 Patología
Keywords: Trilostane Treatment
Cushings-Disease
Issue Date: 2013
Journal: Clinical Endocrinology of Companion Animals
Abstract: This chapter discusses the pathogenesis, classical signs, diagnosis, and treatment for hyperadrenocorticism (HAC) in dogs. The clinical signs of HAC result from chronically elevated serum cortisol concentrations. More than 80% of dogs with HAC have pituitary-dependent disease due to an adrenocorticotropic hormone (ACTH)-secreting adenoma; approximately 80% originate in the adenohypophysis and 20% in the intermediate lobe. Older, small breed dogs are predisposed to spontaneous HAC. Tests for spontaneous HAC are divided into screening tests, meant to determine if HAC is present, and differentiating tests, designed to ascertain whether the disease is pituitary-or adrenal-based. Selegiline inhibits the enzyme monoamine oxidase B and, as a result, increases hypothalamic dopamine concentrations, which, in turn, inhibit ACTH secretion from the intermediate lobe of the pituitary. Selegiline is effective in at most 20% of cases of pituitary-dependent HAC.
URI: http://hdl.handle.net/10553/45832
ISBN: 9781118997093
DOI: 10.1002/9781118997093.ch5
Source: Clinical Endocrinology Of Companion Animals, p. 43-64, (2013)
Appears in Collections:Capítulo de libro
Show full item record

SCOPUSTM   
Citations

3
checked on Feb 28, 2021

WEB OF SCIENCETM
Citations

4
checked on Feb 28, 2021

Page view(s)

21
checked on Mar 1, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.